The Future of Biosimilars and Biobetters in Ophthalmology

Abstract

Biosimilars have been spreading widely in the field of ophthalmology since the patent expiry of innovator molecules. The patent of the ranibizumab innovator has already expired, and the aflibercept patent will expire in the next few years. India was the first country to launch the biosimilar of ranibizumab (Razumab, Intas Pharmaceuticals Ltd, Ahmedabad, Gujarat, India) in 2015, whose usage has increased over time. After the US Food and Drug Administration approval of ranibizumab's biosimilar, ranibizumab-nuna (Byooviz™, Biogen, Cambridge, MA, USA), it will be interesting to witness the future of these molecules along with that of biobetters, which are yet to be well defined.